FIG 5 .

Protective efficacy of anti-JEV MAbs in mice. (A and B) Four- to 5-week-old male C57BL/6 mice were passively administered 10 µg of the indicated (A) mouse or (B) human MAb via intraperitoneal injection 1 day prior to inoculation with 10² FFU of JEV-Nakayama via the subcutaneous route. JEV-31 (n = 9), JEV-106 (n = 8), JEV-143 (n = 8), and JEV-169 (n = 10) provided complete protection against lethality. JEV-27 (n = 8), JEV-128 (n = 9), and JEV-131 (n = 9) provided partial protection compared to the isotype control MAbs. (C and D) Three-week-old male C57BL/6 mice were passively administered 10 µg of the indicated MAb as described above 1 day prior to inoculation with 10³ FFU of (C) JEV-MAR 859 (JEV-31, n = 8; JEV-131, n = 9; JEV-169, n = 8) or (D) JEV-2372/79 (JEV-31, n = 9; JEV-106, n = 9; JEV-131, n = 9; JEV-169, n = 9). (E and F) Two hundred fifty micrograms of the indicated MAb was administered 5 days postinfection to (E) 4- to 5-week-old mice infected with 10² FFU of JEV-Nakayama (JEV-31, n = 9; JEV-106, n = 9; JEV-143, n = 9; JEV-169, n = 9; hJEV-75, n = 8) or (F) 3-week-old mice infected with 10³ FFU of JEV-2372/79 (JEV-31, n = 10; JEV-131, n = 9; JEV-143, n = 9; JEV-169, n = 10; hJEV-75, n = 9). Data are pooled from at least two independent experiments. Survival was analyzed for each MAb compared to the isotype control MAb by the log rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.